key: cord-0849458-hh1vll2l
authors: Danziger‐Isakov, Lara; Sester, Martina
title: Unpacking the COVID‐19 vaccine responses: Do we have what we need for a successful trip?
date: 2021-09-20
journal: Am J Transplant
DOI: 10.1111/ajt.16833
sha: c6d1fd6f4c4237c5b816d2b289a6589c26fb9627
doc_id: 849458
cord_uid: hh1vll2l

The authors provide insight on recent articles, including Herrera et al. (page 3971), addressing COVID‐19 vaccine responses in solid organ transplant recipients.

The SARS-CoV-2 pandemic has upended the world and the field of naïve liver and heart recipients. 1 The authors evaluated safety, SARS-CoV-2 IgM/IgG antibody responses and spike-specific cellular immune responses using an ELISpot assay 4 weeks following the second dose of the vaccine in 58 liver and 46 heart transplant recipients. Side effects mirrored those reported in the general population, and no breakthrough COVID-19, no rejection or increase in HLA antibodies were detected. Antibody responses were consistent with previous reports for liver and heart recipients at 71% and 57%, respectively. Interestingly, 86% of liver and 70% of heart recipients showed ELISpot positivity. Overall, decreased responses were associated with vaccination within a year post-transplant and hypogammaglobulinemia. The combined antibody or cellular responses reached 87% in the heart and 93% in liver recipients, which emphasizes the potential value of adding cellular immunity to estimates of overall response rates. Interestingly, a corresponding report in kidney transplant recipients recorded only 65% of patients with humoral or cellular immunity, 2 which may in part be related to the inclusion of more patients within the first year after transplantation (29% kidney compared to 17% liver and 4% heart). In addition, this report excluded individuals with prior COVID-19 by including assessment of humoral and cellular responses at baseline, whereas the heart and liver cohort only considered baseline serology. This may have overestimated cellular response rates to vaccination by potentially including previously infected but antibody negative individuals. Despite these differences, we may be able to gain additional insight into vaccine response. Receipt of anti-thymocyte globulin occurred in 12.8% of kidney recipients but no heart or liver recipients, while lymphopenia was most common in the kidney cohort (28% compared to 21% liver and 9% heart). The impact of mycophenolate is less easily discerned with substantial proportions of both heart (72%) and kidney (61.5%) recipients receiving this agent. 

Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients

Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis

Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients

Occurrence of severe COVID-19 in vaccinated transplant patients